In this book, Yamane attempts to offer fresh perspectives on the current debate on the impact of increased intellectual property rights (IPR) protection on access to medicines. This is an issue which has attracted the attention of several writers with divergent viewpoints, and it can be tempting to quickly skim through the book to discover if there is any new contribution to the debate. The author shifts the focus from the negative impacts of patent protection to the potential benefits that developing countries can derive from the patent system if they put in place and implement appropriate domestic policies, and there is also increased global co-operation in research and development (R&D) between the developed and developing countries.
Yamane admits that lack of access to medicines is an increasingly important issue in developing countries. However, she contends that it is difficult to assess the global innovation effects of IPR protection as there are multiple other factors involved. She argues further that in resolving the problem of access to medicines in developing countries, much emphasis has been placed on the fact that patents only hinder access to medicines by raising prices, instead of on the promotion of dynamic welfare through innovation.
The author holds the opinion that the concept of “flexibilities” in the TRIPS regime has been used by almost all parties to achieve a vague political truce. While she argues that flexibility is necessary and commendable because of the varying situations in countries at different stages of economic and technological development, she does, however, contend that the boundaries of the “flexibilities” have not been defined with precision, and that the extent of permissible national discretion remains controversial. She is sceptical of the view that the “flexibilities” would solve the socioeconomic problems created by IPRS, such as access to medicines, and notes that the extent to which these “flexibilities” have provided solutions remains to be assessed and ascertained. She opines that to foster international co-operation where new technologies and products are created and brought to the market to be widely used, it is necessary to clarify the TRIPS rules instead of “throwing unilaterally interpreted ‘flexibilities’ of the TRIPS Agreement at each other and holding IPRs solely responsible for all kinds of situations” (p. 4).
The book is structured in six parts. The first part (Chapters 1−3) provides a background to the various issues examined in the book. In Chapter 1, the author highlights the fact that IPRs are just one of several factors necessary for promoting creative research and development. In Chapter 2, she discusses the historical development of international Intellectual Property (IP) co-operation and how developing countries also became part of the discussions on the “global patent system”, and she gives an exploration of the various approaches to the patentability of biotechnology inventions in Chapter 3. The second part (Chapters 4−7) focuses on the TRIPS Agreement. In Chapter 4, the author traces the development of TRIPS from the Uruguay Round of Negotiations and the position held by different countries on the divisive controversial questions and how compromises were reached.
The third part of the book examines the issue of access to medicines. In this part she examines the relationship between the TRIPS Agreement and the Doha Declaration on Public Health, which was adopted in response to the problem of access to medicines in developing countries, and the consequent amendment to the TRIPS Agreement (Chapter 9). She notes the flaws in the approach adopted in the discussions before the Declaration was adopted, i.e. the idea that medicines can only be affordable if IPRs are limited. She contends that the problem of access to medicines differs between countries, and focusing on IPRs alone may divert governments’ focus from establishing a strong public health policy and the prudential management of financial and human resources (p. 337).
The fourth part discusses IP and industrial policies. In this part the author argues that IP policies can be effectively utilized as tools of industrial development if combined with co-ordinated efforts to promote scientific and technical skill, and she refers to the development of Japanese Patent Law and its role in increasing the competitiveness of R&D as a suitable model for emerging economies in this regard (Chapter 10). In the fifth part of the book, the author considers TRIPS “flexibilities”, and she focuses on patentable subject matter, and patentability requirements with special attention to the prohibition of “evergreening” under the Indian Patents Act (Chapter 12). Chapter 13 discusses data exclusivity. Chapter 14 examines the “TRIPS plus” provisions in US Free Trade Agreements, and she suggests that the socioeconomic impact of these provisions will depend on factors external to the text of the agreements and how they are implemented.
In the final part, Yamane concludes with the suggestion that research-based pharmaceutical companies should establish a voluntary fund for providing technical assistance for developing countries. The fund would be useful in the transfer of know-how to help build medicine distribution systems or to strengthen the foundation of clinical R&D to improve access to expensive drugs. She argues that such a transfer of know-how could eventually assist developing countries recognize the connection between R&D and IPRs. She notes that “arguing about TRIPS ‘flexibilities’ and TRIPS plus, in a new Tower of Babel, may become an excuse for not making real efforts to ensure that new technologies are developed” (p. 518). She takes the view that harping on about IPR alone, either as a key promoter of innovation or as an obstacle to economic development, lacks proper perspective, and IP policies have to be linked with other policies that will encourage creative research. IPR protection should be viewed as part of the larger effort to encourage innovation through integrated national policies and international co-operation. The book makes an attempt to examine the issues dispassionately from the perspective of both developed and developing countries and it is recommended as an excellent work on international patent law and policy.
